Skip to content

Pre-ART Retention in Care in Tanzania

Retention and Engagement in Care of Patients Prior to ART Initiation in the Kagera Region of Tanzania

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01992887
Acronym
PARC
Enrollment
948
Registered
2013-11-25
Start date
2012-03-31
Completion date
2016-02-29
Last updated
2016-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS (Acquired Immunodeficiency Syndrome), HIV (Human Immunodeficiency Virus)

Keywords

HIV/AIDS, Retention, ART (anti-retroviral therapy) ineligible

Brief summary

Retention of patients in HIV care following diagnosis and enrollment is critical to the long-term success of HIV care and treatment scale-up. The goal of this study is to better understand the factors that influence retention and engagement in HIV care among adult patients who are enrolled in HIV care and are not yet eligible for antiretroviral therapy (ART). The study will be conducted at four HIV care and treatment clinics (CTCs) in Kagera Region, Tanzania. This is a mixed-methods study with both qualitative (interviews) and quantitative (surveys) data collection. Our findings will be important towards designing programs that help patients remain in HIV care.

Detailed description

Retention of patients in HIV care following diagnosis and enrollment is a chronic challenge in both resource rich and resource poor settings (Rosen, Fox et al. 2007; WHO 2009; Fox and Rosen 2010), and is critical to the long-term success of HIV care and treatment scale-up. Most research on retention in care has focused on persons who are eligible for or have initiated antiretroviral therapy (ART), generally examined only demographic and clinical determinants. However, a large proportion of patients enrolled in HIV care (e.g., 45%, according to our data from 722 sub-Saharan African clinics) have not been determined to be ART-eligible and have not yet initiated ART; among these individuals, even less is known about the magnitude and determinants of non-retention in care. Retention in HIV care prior to ART initiation is a pre-requisite to: 1) optimal prophylaxis, diagnosis, and treatment of opportunistic illnesses (OIs); 2) effective secondary prevention of HIV transmission, such as by patient counseling and education, earlier diagnosis of infected family members and sexual partners, and prevention of mother to child transmission (PMTCT); and 3) more timely ART initiation. Retention in care among patients at earlier disease stages is also increasingly important given the WHO-recommended expansion of ART eligibility guidelines in resource-limited settings (WHO 2009). Objective: The goal of this study is to better understand barriers and enablers to retention and engagement in HIV care among adult patients who are enrolled in HIV care and are not yet eligible for ART. The specific objectives are: 1. To describe themes in barriers and enablers to retention and engagement in HIV care; 2. To conduct structured interviews to gather relevant baseline information on potential determinants of non-retention and non-engagement in HIV care; 3. To estimate the incidence of short-term outcomes (missed visits and lost to follow-up (LTF)), including the rate and proportion of those LTF who are no longer engaged in HIV care; and 4. To identify determinants of missed visits, LTF, and non-engagement in care among ART-ineligible patients. Methods: This study will be conducted using qualitative and quantitative methods at four HIV care and treatment clinics (CTCs) in Kagera Region, Tanzania. 1. Qualitative: in-depth interviews at two CTCs with up to 20 adult patients (ART naïve, and ineligible or indeterminate for ART) and about 4 health care workers; and focus group discussions (about 4 groups of about 6-10 persons/group) with adult patients (ART naïve, and ineligible or indeterminate for ART). 2. Quantitative: 1) structured baseline interviews at four CTCs (n= approximately 900 adult patients who are ART naïve, and ineligible or indeterminate for ART); 2) prospective monitoring of these 900 patients using routine CTC patient data to assess missed visits and LTF; and 4) brief structured surveys of patients who become LTF and are reached through defaulter tracing efforts.

Interventions

None listed

Sponsors

Ministry of Health and Social Welfare, Tanzania
CollaboratorOTHER_GOV
National Institute of Mental Health (NIMH)
CollaboratorNIH
Columbia University
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

QUALITATIVE COHORT In-depth key informant interviews and focus groups will be conducted with patients that meet the following criteria: ART-eligibility indeterminate patients (n= approximately 10 in-depth and up to 20 focus group participants, where half are from a rural site, Mugana District Hospital and half are from an urban site, Nyakahanga District Hospital) i) Inclusion criteria: * ≥18 years of age * ART naïve (unless for prior PMTCT) * made at least one clinic visit prior to study enrollment * unknown ART eligibility, * willing to give informed consent. ii)

Exclusion criteria

* \<18 years of age * initiated ART other than PMTCT prior to enrollment * have known ART eligibility or ineligibility * not willing to give informed consent. ART-ineligible patients (n= approximately 10 in-depth and up to 20 focus group participants, where half are from a rural site, Mugana District Hospital and half are from an urban site, Nyakahanga District Hospital) i) Inclusion criteria: * ≥18 years of age * ART naïve (unless for prior PMTCT) * made at least one clinic visit prior to study enrollment * known ART ineligibility * willing to give informed consent. ii)

Design outcomes

Primary

MeasureTime frame
Proportion of those lost to follow-up (LTF) who are no longer engaged in HIV care24 months

Countries

Tanzania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026